Work at collaboration

In some companies, creating strategies for global clinical trials supply has been carried out in done in silos, with the research teams finding the cheapest source for drug candidates prior to clinical trials, and then development teams tracking down a more reliable source for later stage trials involving much larger patient populations in the clinic.

However, changing CMO part way through development can cause problems, or at the very least, can lead to delays in the drug development process.

Lack of communication between teams and groups can lead to hitches and delays between preclinical and clinical stages, or between formulation and manufacturing steps. The key to improved reliability of clinical drug supply and smoother drug development is better collaboration, between different departments and specialist groups.

Collaboration is also important between drug development companies, their manufacturing partners, and their clinical trial partners. Working more closely together can reduce the risk of issues with supply overall or at specific clinical trial sites, reducing the delays in getting drugs through clinical trials and onto the market, which is after all everyone's aim. It also allows companies to be pre-warned about any forthcoming issues, giving them time to get contingency plans in place.

Work at collaboration

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.